Advanced Surgery Advantage

A data-driven, evidence-based hemostasis optimization program

The Burden of Bleeding

30%

Average rate of bleeding complications during surgery1

6 Days

Length of stay associated with bleeding-related complications or transfusions1

$10K+

Potential incremental cost of bleeding complications per patient hospitalisation for major surgeries1

The Challenge of Surgical Bleeding

Surgical bleeding can lead to complications and increased allogeneic blood utilisation creating headwinds to meeting your performance measures.

Surgical bleeds are associated with increased complication rates in1:

Surgical revisions

Transfusions

Length of stay

Increased resource utilisation 

Focus on blood management protocols emphasising intraoperative interventions, including use of topical haemostatic agents, can help mitigate these challenges.

ASA wheel

What Is Advanced Surgery Advantage?

Advanced Surgery Advantage is a data-driven, evidence-based haemostasis optimisation programme. It supports hospital initiatives aimed at:

Reducing intraoperative blood loss

Reducing blood transfusions

Optimising patient outcomes after surgery

Reducing waste

Cost avoidance

It provides an approach to partnering with hospitals in support of their goals and quality initiatives.

Image of three connected circles related to Vital Edge - Clinical Efficacy, Financial Performance and Operational Efficiency

Efficiencies in the Operating Room

Through Advanced Surgery Advantage, Baxter’s Advanced Surgery team partners with hospitals in support of their goals and quality programs. Advanced Surgery Advantage provides actionable insights and practical solutions related to intraoperative haemostasis that will help healthcare providers realise marked improvements in three, interconnected areas of surgical care:

Clinical efficacy

Financial performance

Operational efficiency

Program Features

Advanced Surgery Advantage offers several potential collaboration opportunities

Live Utilisation Review

To help hospitals assess their current state of hemostat utilization, Baxter Medical Affairs conducts unbiased observation reviews of hemostat and sealant use, resulting in a detailed report of findings and improvement opportunities

Health Economic Assessment

To help hospitals quantify potential economic cost savings, Baxter Market Access works with hospitals to create a model to assess potential savings and measure results after implementing improvement opportunities

Patient Blood Management

To help hospitals assess the impact of implementing an intraoperative hemostasis protocol to reduce transfusions, Baxter Market Access supports operating room and blood bank staff in identifying clinical endpoints and evaluation criteria to measure the success of improvement initiatives

Baxter takes safety of our products and patients very seriously. If you would like to report an adverse event with Baxter drugs (e.g. Tisseel, Artiss, …), you can contact Baxter directly: [email protected], or you can report it via Netherlands Pharmacovigilance Center Lareb’s website: www.lareb.nl Any medical device product quality complaints (including medical device adverse incidents) relating to Baxter products should be sent to EMEA SHS Complaints Intake [email protected]